Pacira BioSciences Enters New Agreements, Terminates Others
Ticker: PCRX · Form: 8-K · Filed: Jul 7, 2025 · CIK: 1396814
| Field | Detail |
|---|---|
| Company | Pacira Biosciences, Inc. (PCRX) |
| Form Type | 8-K |
| Filed Date | Jul 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, agreement-termination
Related Tickers: PCRX
TL;DR
Pacira BioSciences just signed new deals and ditched old ones, creating new financial obligations.
AI Summary
On July 3, 2025, Pacira BioSciences, Inc. entered into a material definitive agreement and simultaneously terminated another. The company also created a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details regarding the nature of these agreements, the counter-parties, and the financial implications were not provided in this initial filing.
Why It Matters
This filing indicates significant changes in Pacira BioSciences' contractual and financial obligations, which could impact its future operations and financial health.
Risk Assessment
Risk Level: medium — The filing indicates material changes to agreements and financial obligations, the specifics of which are not yet detailed, creating uncertainty.
Key Players & Entities
- Pacira BioSciences, Inc. (company) — Registrant
- July 3, 2025 (date) — Date of Earliest Event Reported
FAQ
What is the nature of the material definitive agreement entered into by Pacira BioSciences?
The filing states that Pacira BioSciences entered into a material definitive agreement on July 3, 2025, but does not provide specific details about its terms or counter-parties.
Which material definitive agreement was terminated by Pacira BioSciences?
The filing indicates the termination of a material definitive agreement on July 3, 2025, but does not specify which agreement it was.
What type of financial obligation was created by Pacira BioSciences?
Pacira BioSciences created a direct financial obligation or an obligation under an off-balance sheet arrangement on July 3, 2025, with the specifics not detailed in this report.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 3, 2025.
What are the primary items of information disclosed in this 8-K filing?
This 8-K filing discloses the entry into a material definitive agreement, the termination of a material definitive agreement, and the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 7, 2025 regarding Pacira BioSciences, Inc. (PCRX).